← All trials
NCT04332523
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2020
- Primary completion
- Mar 23, 2021
- Completion date
- Mar 23, 2021
- First posted
- Apr 2, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.